Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07095205 · ClinicalTrials.gov registry record · Phase 4

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

A Phase 4 study of Major Depressive Disorder (MDD), sponsored by Stony Brook University.

Recruiting
Registry status
Phase 4
Development phase
14
Enrollment target
1
Study location

NCT07095205 is a Phase 4 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Stony Brook University. The registered enrollment target is 14 participants, below the 158-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07095205, a Phase 4 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Stony Brook University.

RECRUITING
Registry status
Phase 4
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Conditions Studied

Major Depressive Disorder (MDD)

Interventions

  • DRUG Nicotine transdermal patch
  • DRUG PET Scan with [18F] VAT

Study Locations (1)

New York

  • Stony Brook University: Dept of Psychiatry - Stony Brook

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2024-10-03
Est. Completion 2029-09-30
Phase Phase 4

Sponsor

Stony Brook University

127 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07095205

The ClinicalTrials.gov registry entry for NCT07095205 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (91% lower). The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Nicotine transdermal patch is the first listed.

NCT07095205 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07095205 about?

NCT07095205 is a clinical study titled "PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.". In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to unde...

What is the current status of trial NCT07095205?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2024-10-03. Estimated completion is 2029-09-30.

What conditions does trial NCT07095205 study?

This clinical trial studies the following conditions: Major Depressive Disorder (MDD).

What interventions are being tested in trial NCT07095205?

The interventions under investigation include: Nicotine transdermal patch (DRUG), PET Scan with [18F] VAT (DRUG).

Who is sponsoring clinical trial NCT07095205?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07095205 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder (MDD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder (MDD)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.